AVI-4065

DB05620InvestigationalSmall molecule

AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of...

Mechanism: AVI-4065 is a virus replication inhibitor (antisense).
Curator reviewed
Primary indication: Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
Code names: AVI-4065

Resolves to

Targets

O39930NS5bQ91RS4NS3 protease

What you can answer from here — as of July 03, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with AVI-4065, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account